NF-kappa B Inhibitors Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Complexa, Accendatech, Serenex, OncoViRx, Novo Nordisk

The NF-kappa B Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“NF-kappa B Inhibitors Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the NF-kappa B Inhibitors Market.

Some of the key takeaways from the NF-kappa B Inhibitors Pipeline Report:

• Companies across the globe are diligently working toward developing novel NF-kappa B Inhibitors treatment therapies with a considerable amount of success over the years. 
• NF-kappa B Inhibitors companies working in the treatment market are SFA Therapeutics, ILIAS Biologics, CURACLE, First Wave Bio, Inc., Accendatech, GeneOne Life Science, AnGes, BioVie Inc., Complexa,  Accendatech, Serenex, OncoViRx, Novo Nordisk, Profectus Biosciences, Mitsubishi Tanabe Pharma, ImmuneTarget, Merck Serono, EntreChem, Link Health Group, and others, are developing therapies for the NF-kappa B Inhibitors treatment 

• Emerging NF-kappa B Inhibitors therapies in the different phases of clinical trials are- SFA 001, ILB 202, CU 103, Niclosamide, ACT 001, GLS-1027, AMG 0101, NE3107, CXA-10, ACT001, and others are expected to have a significant impact on the NF-kappa B Inhibitors market in the coming years.   
• In January 2022, “Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias” is the name of a trial started by BioVie Inc. This study uses advanced neuroimaging techniques to measure changes in inflammatory and metabolic parameters that can be measured in the central nervous system (CNS) in patients treated with NE3107 (17a-ethynyl-androst-5-3b,7b,17b-triol) as well as changes in Alzheimer’s disease biomarkers
• In September 2022, Topline findings from a Phase II clinical trial of NE3107 for the treatment of Alzheimer’s disease (AD) were released by BioVie Inc. The majority of patients’ measures improved with the use of NE3107, according to preliminary findings, however individuals with MCI or mild AD experienced more improvement
• In August 2021, “A Phase 3, Double Blind, Randomised, Placebo Controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Probable Alzheimer’s Disease” is the name of the experiment that BioVie Inc. started

NF-kappa B Inhibitors Overview

NF-kappa B, a family of inducible transcription factors, is a nuclear factor kappa light chain enhancer of activated B cells.

Get a Free Sample PDF Report to know more about NF-kappa B Inhibitors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/nf-kappa-b-inhibitors-pipeline-insight

Emerging NF-kappa B Inhibitors Drugs Under Different Phases of Clinical Development Include:

• SFA 001: SFA Therapeutics
• ILB 202: ILIAS Biologics
• CU 103: CURACLE
• MK-7110: Merck
• NE3107: NeurMedix
• AMG 0101 (NF-κB Decoy Oligodeoxynucleotide): AnGes
• Imx-110: Immix Biopharma
• Niclosamide: First Wave Bio, Inc.
• ACT 001: Accendatech
• GLS-1027: GeneOne Life Science
• AMG 0101: AnGes
• NE3107: BioVie Inc.
• CXA-10: Complexa
• ACT001: Accendatech

Route of Administration

NF-kappa B Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Topical
• Oral
• Intravenous
• Parenteral
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Gene Therapies
• Peptides
• Oligonucleotides
• Small molecule
• Product Type

NF-kappa B Inhibitors Pipeline Therapeutics Assessment

• NF-kappa B Inhibitors Assessment by Product Type
• NF-kappa B Inhibitors By Stage and Product Type
• NF-kappa B Inhibitors Assessment by Route of Administration
• NF-kappa B Inhibitors By Stage and Route of Administration
• NF-kappa B Inhibitors Assessment by Molecule Type
• NF-kappa B Inhibitors by Stage and Molecule Type

DelveInsight’s NF-kappa B Inhibitors Report covers around 10+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further NF-kappa B Inhibitors product details are provided in the report. Download the NF-kappa B Inhibitors pipeline report to learn more about the emerging NF-kappa B Inhibitors therapies

Some of the key companies in the NF-kappa B Inhibitors Therapeutics Market include:

Key companies developing therapies for NF-kappa B Inhibitors are – Catabasis Pharmaceuticals, OncoImmune , Almirall, Takeda Oncology, Biogen, Reata Pharmaceuticals, LG Life Sciences , Complexa, Dong-A ST, AnGes, Accendatech, ILIAS Biologics , Merry Life Biomedical Company , Innate Biologics, Profectus Biosciences, Serenex, Novo Nordisk, OncoViRx, Leuchemix, Mitsubishi Tanabe Pharma, Othera Pharmaceuticals, Nereus Pharmaceuticals, Anesiva, ImmuneTarget , GlaxoSmithKline, Astellas Pharma, ImStar Therapeutics, AstraZeneca, AbbVie, Perrigo Company, Gilead Sciences, Baxter Healthcare Corporation, AnGes MG, Complexa, OncoViRx, Merck Serono, EntreChem, Link Health Group, and others.

NF-kappa B Inhibitors Pipeline Analysis:

The NF-kappa B Inhibitors pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of NF-kappa B Inhibitors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NF-kappa B Inhibitors Treatment.
• NF-kappa B Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• NF-kappa B Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NF-kappa B Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about NF-kappa B Inhibitors drugs and therapies

NF-kappa B Inhibitors Pipeline Market Drivers

• Increase in prevalence of cancer patients worldwide, NF-κB – A well-studied and mapped out target are some of the important factors that are fueling the NF-kappa B Inhibitors Market.

NF-kappa B Inhibitors Pipeline Market Barriers

• However, detrimental effects associated with in-vivo inhibition of NF-κB, lack of specificity in inhibiting distinct NF-κB complexes and other factors are creating obstacles in the NF-kappa B Inhibitors Market growth.

Scope of NF-kappa B Inhibitors Pipeline Drug Insight    

• Coverage: Global
• Key NF-kappa B Inhibitors Companies: SFA Therapeutics, ILIAS Biologics, CURACLE, First Wave Bio, Inc., Accendatech, GeneOne Life Science, AnGes, BioVie Inc., Complexa,  Accendatech, Serenex, OncoViRx, Novo Nordisk, Profectus Biosciences, Mitsubishi Tanabe Pharma, ImmuneTarget, Merck Serono, EntreChem, Link Health Group, and others
• Key NF-kappa B Inhibitors Therapies: SFA 001, ILB 202, CU 103, Niclosamide, ACT 001, GLS-1027, AMG 0101, NE3107, CXA-10, ACT001, and others
• NF-kappa B Inhibitors Therapeutic Assessment: NF-kappa B Inhibitors current marketed and NF-kappa B Inhibitors emerging therapies
• NF-kappa B Inhibitors Market Dynamics: NF-kappa B Inhibitors market drivers and NF-kappa B Inhibitors market barriers 

Request for Sample PDF Report for NF-kappa B Inhibitors Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services